[1]王 娜,杨 琳△.薤白通脉汤加减对冠心病不稳定型心绞痛患者中医证候积分及血清VEGF、Hcy水平的干预作用*[J].陕西中医,2020,(10):1388-1391.[doi:DOI:10.3969/j.issn.1000-7369.2020.10.013]
　WANG Na,YANG Lin..Effect of Xiebai Tongmai decoction on TCM syndrome score and serum VEGF and Hcy levels in patients with unstable angina pectoris of coronary heart disease[J].,2020,(10):1388-1391.[doi:DOI:10.3969/j.issn.1000-7369.2020.10.013]
点击复制

薤白通脉汤加减对冠心病不稳定型心绞痛患者中医证候积分及血清VEGF、Hcy水平的干预作用*
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2020年10期
页码:
1388-1391
栏目:
临床研究
出版日期:
2020-10-05

文章信息/Info

Title:
Effect of Xiebai Tongmai decoction on TCM syndrome score and serum VEGF and Hcy levels in patients with unstable angina pectoris of coronary heart disease
作者:
王 娜1; 杨 琳2△
1.西安市中医医院心血管内科(西安 710021); 2.陕西省杨凌示范区医院(杨凌 712100)
Author(s):
WANG Na; YANG Lin.
Department of Cardiology,Xi'an Hospital of Traditional Chinese Medicine(Xi'an 710021)
关键词:
薤白通脉汤加减;  不稳定型心绞痛;  中医证候积分;  血管内皮生长因子;  同型半胱氨酸;  内皮素
Keywords:
Xiebai Tongmai decoction;  Unstable angina;  TCM syndrome score;  Serum vascular endothelial growth factor;  Homocysteine;  Endothelin
分类号:
R541.4
DOI:
DOI:10.3969/j.issn.1000-7369.2020.10.013
文献标志码:
A
摘要:
目的:探讨薤白通脉汤加减对冠心病不稳定型心绞痛(UAP)患者中医证候积分及血清血管内皮生长因子(VEGF)、同型半胱氨酸(Hcy)水平的干预作用。方法:选取122例UAP患者进行前瞻性研究,简单随机化分组,各61例。对照组予以常规治疗,于此基础上,观察组予以薤白通脉汤加减治疗,比较两组治疗前、治疗后中医证候积分、中医证候疗效、心电图疗效、内皮功能指标[血清一氧化氮(NO)、内皮素(ET)]水平、血清VEGF、Hcy水平。结果:观察组治疗后中医证候积分较对照组低(P<0.05); 观察组中医证候疗效(93.44%)优于对照组(80.33%,P<0.05); 观察组心电图疗效(91.80%)优于对照组(77.05%,P<0.05); 观察组治疗后血清NO水平较对照组高,ET水平较对照组低(P<0.05); 观察组治疗后血清VEGF水平较对照组高,Hcy水平较对照组低(P<0.05); 两组不良反应发生率(9.84%与6.56%)相比,差异无统计学意义(P>0.05)。结论:薤白通脉汤加减治疗冠心病不稳定型心绞痛,可缓解患者心绞痛、心肌缺血等临床症状,改善患者动脉粥样硬化情况与血管内皮功能,疗效显著。
Abstract:
Objective:To investigate the intervention effect of Xiebai Tongmai decoction on TCM syndrome scores and serum vascular endothelial growth factor(VEGF)and homocysteine(Hcy)levels in patients with unstable angina pectoris(UAP).Methods:A total of 122 patients with UAP were enrolled in the study.A randomized randomized group of 61 patients was included.The control group received routine treatment.On the basis of this,the observation group was treated with Xiebai Tongmai decoction.The TCM syndrome scores before and after the treatment,the efficacy of TCM syndromes,the electrocardiogram efficacy,and the endothelial function index(serum oxidation)were compared.Nitrogen(NO),endothelin(ET)levels,serum VEGF,Hcy levels.Results:The scores of TCM syndromes in the observation group were lower than those in the control group(P<0.05).The efficacy of TCM syndromes in the observation group(93.44%)was better than that in the control group(80.33%),(P<0.05).The electrocardiogram effect of the observation group was 91.80%,superior to the control group(77.05%P<0.05); the serum NO level in the observation group was higher than that in the control group,and the ET level was lower than that in the control group(P<0.05).The serum VEGF level in the observation group was higher than that in the control group.High,Hcy levels were lower than those in the control group(P<0.05); there was no significant difference between the two groups(9.84% vs 6.56%)(P>0.05).Conclusion:Xiebai Tongmai decoction can reduce the unstable angina pectoris of coronary heart disease,relieve the clinical symptoms such as angina pectoris and myocardial ischemia,improve the atherosclerosis and vascular endothelial function of patients.

参考文献/References:

[1] Wu SW,Pan Q,Chen T,et al.Research of medical expenditure among inpatients with unstable angina pectoris in a single cente[J].Chin Med J(Engl),2017,130(13):1529-1533.
[2] 黄国圣.中西医结合治疗不稳定性心绞痛35例临床观察[J].中医药导报,2016,22(3):73-74.
[3] 何晓玲,何 刚,刘傲霜,等.活血化瘀通络汤对冠心病不稳定型心绞痛患者C反应蛋白及血流动力学的影响[J].湖北中医药大学学报,2016,18(5):41-44.
[4] 刘曼华,尹 琼.不稳定型心绞痛患者血管内皮生长因子水平变化及其相关因素分析[J].中国心血管病研究,2017,15(4):342-345.
[5] 舒 放,王海峰,薛飞肖,等.不同性别MTHFR基因多态性协同叶酸水平差异对血清同型半胱氨酸的影响研究[J].陕西医学杂志,2019,48(9):1119-1121,1125.
[6] 陈灏珠,钟南山,陆再英.内科学[M].8版.北京:人民卫生出版社,2013:227.
[7] 周仲英.中医内科学[M].2版.北京:中国中医药出版社,2007:135-142.
[8] 齐 锋,靳宏光,王义强,等.基于痰瘀伏邪理论干预大鼠冠状动脉微血栓炎症因子实验研究[J].中华中医药学刊,2016,34(5):1055-1057.
[9] Yao ZH,Qin ZF,Dai Y,et al.Phytochemistry and pharmacology of Allii Macrostemonis Bulbus,a traditional Chinese medicine[J].Chin J Nat Med,2016,14(7):481-498.
[10] 杨 帆.瓜蒌薤白半夏汤合涤痰汤加减治疗痰浊闭阻型胸痹心痛临床观察[J].陕西中医,2017,38(2):178-179.
[11] 卓小岸,欧阳艳红,何 平,等.替格瑞洛用于氯吡格雷抵抗性AMI患者的疗效及对细胞炎症反应的影响[J].中国急救复苏与灾害医学杂志,2020,15(1):38-41.
[12] 王晓萍,赵井辉,田 鑫,等.替格瑞洛联合阿托伐他汀在降低冠心病患者PCI术后不良心脏事件及再狭窄中的应用研究[J].陕西医学杂志,2018,47(2):241-243.
[13] 沈云峰,张洪波,郭浩浩,等.冠心病患者ADMA、eNOS和NO水平变化及与Gensini评分的相关性[J].微循环学杂志,2018,28(3):35-38.
[14] 孙文锦,其布热.血浆巨噬细胞移动抑制因子水平变化与ST段抬高型心肌梗死患者多因素相关性分析及远期预后[J].中国急救复苏与灾害医学杂志,2020,15(2):196-200.
[15] Liu W,Wang T,Sun P,et al.Expression of Hcy and blood lipid levels in serum of CHD patients and analysis of risk factors for CHD[J].Exp Ther Med,2019,17(3):1756-1760.

相似文献/References:

[1]郭 娜.汗法治疗阴寒凝滞型不稳定性心绞痛疗效及对患者血浆CRP、ET-1和NO的影响*[J].陕西中医,2020,(4):465.
[2]吴月红,张 利.开郁活血通痹汤治疗气滞血瘀型不稳定型心绞痛疗效及对患者心功能的影响[J].陕西中医,2021,(7):890.[doi:DOI:10.3969/j.issn.1000-7369.2020.07.020]

备注/Memo

备注/Memo:
*国家自然科学基金资助项目(81673115)
更新日期/Last Update: 2020-10-10